A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
Wanjun YuFei YeXiao YuanYali MaChaoming MaoXiaoqin LiJian LiChunhua DaiFenhong QianJunrong LiXiujuan FanYuepeng ZhouDeqiang WangZhenhong GuoHuazhang AnMinghui ZhangDeyu ChenSheng XiaPublished in: BMC cancer (2021)
This trial (Phase I/II Trails of NKT Cell in Combination With Gefitinib For Non Small Cell Lung Cancer) was registered on 21 November 2017 with www.chictr.org.cn , ChiCTR-IIR-17013471 .
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- clinical trial
- phase ii
- induced apoptosis
- study protocol
- phase iii
- tyrosine kinase
- cell cycle arrest
- single cell
- cell therapy
- open label
- lymph node metastasis
- randomized controlled trial
- endoplasmic reticulum stress
- cell death
- stem cells
- squamous cell carcinoma
- signaling pathway
- mesenchymal stem cells
- bone marrow